-44%

est. 2Y upside i

HealthcareSeries B

Design semantically precise and biologically grounded prompts for large AI models used in genomic inference, synthesis design, and ancestral modeling. Co-founded by the CEO of Colossal Biosciences, Ben Lamm.

Rank

#778

Sector

AI in Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Astromech presents a moderate upside opportunity with higher risk, typical for a Series B company in a high-growth sector.

Last updated: March 10, 2026

Bull (35%)+250%

Astromech's proprietary AI platform achieves significant breakthroughs in biological data analysis and design, leading to key partnerships with major pharmaceutical companies or successful early-stage drug discovery programs. This drives rapid revenue growth and justifies a $700M+ valuation by 2028, reflecting its strong competitive moat and leadership in a niche but critical AI-biotech subdomain.

Base (45%)+50%

The company successfully develops and commercializes its initial AI tools, gaining traction with a segment of biotech and life science researchers. Growth is steady but faces competition from both specialized startups and in-house efforts by larger incumbents, leading to an acquisition at a $300M valuation by 2030, providing a moderate return for common shareholders.

Bear (20%)-60%

Development of proprietary AI proves more challenging or slower than anticipated, or a dominant incumbent like Tempus AI or a major pharmaceutical company launches a highly competitive, well-resourced platform. This leads to slower adoption, difficulty securing follow-on funding, and a down round or distressed acquisition at an $80M valuation, significantly eroding common stock value after liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Investors hold $30M in liquidation preferences. In an exit at or below the estimated $200M valuation, common shareholders would receive value only after this $30M is paid, effectively reducing the common equity value.

Dilution Risk

high

As a Series B company, Astromech will likely require multiple additional funding rounds, leading to further dilution for current equity holders.

Secondary Liquidity

none

There are currently no active secondary markets or tender offers for Astromech's equity, meaning employee shares are illiquid.

Other — 1 role

View all 1 open roles at Astromech →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Astromech's data — designed to show you've done your homework.

  • 1

    “Given the 'stealth mode' operation, what are the key product development milestones Astromech aims to achieve in the next 12-18 months, and how will success be measured?”

  • 2

    “With major AI players like Nvidia and Tempus AI investing heavily in AI for drug discovery, how does Astromech plan to differentiate its proprietary AI technologies and defend its market position against these well-funded incumbents?”

  • 3

    “Considering the Series B funding and the typical runway for biotech AI companies, what is the anticipated timeline for the next funding round, and how is the company thinking about eventual liquidity events for employees?”

Community

Valuation Sentiment

Our model estimates -44% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.